[Treatment of deep venous thrombosis with fractions of low molecular weight heparin]. 1988

R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat

UI MeSH Term Description Entries
D010690 Phlebography Radiographic visualization or recording of a vein after the injection of contrast medium. Venography,Phlebographies,Venographies
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses

Related Publications

R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
February 1988, Presse medicale (Paris, France : 1983),
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
November 1991, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
January 1995, Revue medicale de Bruxelles,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
November 1988, Lancet (London, England),
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
November 1988, JAMA,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
September 1999, The Journal of family practice,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
April 2002, Thrombosis research,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
October 1998, The Western journal of medicine,
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
December 1999, Managed care (Langhorne, Pa.),
R Faivre, and D Ducellier, and Y Kieffer, and J P Bassand, and J P Maurat
November 1999, Presse medicale (Paris, France : 1983),
Copied contents to your clipboard!